« Comparison of Mydriatic Regimens Used in Screening for Retinopathy of Prematurity in Preterm Infants With Dark Irides | Main | Automated Lamellar Keratoplasty for Recurrent Granular Corneal Dystrophy After Phototherapeutic Keratectomy »
May 28, 2005
Prolonged Antiscarring Effects of Ilomastat and MMC after Experimental Glaucoma Filtration Surgery
Investigative Ophthalmology and Visual Science. 2005;46:2018-2022
In a randomized, prospective, masked-observer study, 21 New Zealand White rabbits underwent modified GFS. The animals were allocated to receive either intraoperative mitomycin-C (MMC) at a concentration of 0.2 mg/mL or postoperative subconjunctival injections of either ilomastat or phosphate-buffered saline (PBS).RESULTS. Ilomastat significantly improved surgical outcome compared with vehicle (P < 0.0163) and length of bleb survival was similar to the MMC group. The mean day of failure was 46.2 (range, 42–60) with ilomastat, 51.3 (range, 49–60) with MMC, and 16 (range, 15–21) with vehicle. IOP maintenance with ilomastat was similar to that in the MMC group. Histologically, minimal scar tissue was seen with MMC and ilomastat. MMC-treated tissue demonstrated subconjunctival hypocellularity associated with peripheral fibrosis. Ilomastat resulted in normal-appearing conjunctival morphology.CONCLUSIONS. Ilomastat successfully prolongs bleb survival. MMP inhibition may provide an additional, potentially safer method of controlling intraocular pressure, thus preventing failure of glaucoma surgery, and may also act as a potential adjuvant treatment when MMC alone is inadequate.
Posted by mehdi khanlari at May 28, 2005 11:31 PM